AccessibilityHelp
Yd Bio logo

Yd Bio(NASDAQ) YDES

Market Cap$408.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-45%
5 Year-43%
1 Year-69%
1 Month+119%
$4.23
-26.69%
-1.54Today
After hours$4.31+$0.08 (+1.89%)
Yd Bio last closing stock price
MetricPriceDate
Last closeUSD 5.772026-10-21
Yd Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.28%USD 6.362026-10-14
1 month+119.39%USD 2.632026-09-21
3 month+182.84%USD 2.042026-07-23
Year to date-52.67%USD 12.192025-12-31
1 year-68.86%USD 18.532025-10-21
3 year-48.9%USD 11.292023-10-20
5 year-43.04%USD 10.132021-10-22
Since inception-44.52%USD 10.402020-12-23

Yd Bio Financials at a Glance

Market Cap

$408.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.97M

EPS (TTM)

$0.00

P/E Ratio

-5.84

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$4.23

Volume

180,440.504

Open

$5.85

Previous Close

$4.24

Daily Range

$4.15 - $6.04

52-Week Range

$1.70 - $18.57

Estimated Earnings Date

N/A

YDES News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yd Bio

YD Bio Limited is a biopharmaceutical company specializing in regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company focuses on innovative treatments for eye diseases and offers a range of healthcare products.

Products and Services
  • 3D LensMate Artificial Tears for dry eye relief
  • LSC Eye Drug/Injection for retinal and macular disorders
  • Clinical trial supply chain services for pharmaceutical companies
Growth Outlook
  • Expansion into the U.S. market enhances growth potential
  • Innovative product pipeline targeting unmet medical needs
  • Strategic partnerships with biotechnology firms for collaboration
Financial Highlights
  • Recent quarterly net income of -$2.2 million reflects ongoing investments
  • Trailing twelve months (TTM) cash ratio of 3.66 indicates strong liquidity
  • Market capitalization of $419 million supports growth initiatives
YD Bio Limited is positioned in the biotechnology sector, focusing on innovative solutions for eye health and clinical services. The company has developed a range of products aimed at treating various eye conditions, including dry eye syndrome and retinal disorders. With a commitment to research and development, YD Bio Limited is actively pursuing opportunities to expand its market presence, particularly in the United States. The growth outlook for YD Bio Limited appears promising, driven by its innovative product pipeline and strategic partnerships. The company's focus on addressing unmet medical needs in the eye care sector positions it well for future growth. Recent financial data indicates a commitment to investment in research and development, which may lead to long-term benefits despite current net losses. Financially, YD Bio Limited has demonstrated a strong liquidity position, as evidenced by its cash ratio. The company's market capitalization reflects investor confidence in its growth potential. As YD Bio Limited continues to innovate and expand its offerings, it may attract further interest from investors looking for opportunities in the biotechnology sector.
AI Generated • Oct 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Ethan Shen, PhD, EMBA

Website

www.ydesgroup.com

Headquarters

Taipei, TP 115001, TW

YDES Financials

Key Financial Metrics (TTM)

Gross Margin

-7.06%

Operating Margin

-883.31%

Net Income Margin

-1392.61%

Return on Equity

-445.10%

Return on Capital

N/A

Return on Assets

-60.32%

Earnings Yield

-17.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$408.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.84M

Volume

180.44K

Avg. Volume

291.47K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.38M

EBITDA

-$2.99M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$3.00

Free Cash Flow

-$1.18M

Cash & ST Invst.

$2.66M

Total Debt

$5.00K

Yd Bio Performance Analysis

Yd Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 510,360N/A
20252025-12-31USD 596,81716.9%
Yd Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q22026-06-30N/A
Yd Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.41-31.5%
20232023-12-31USD -0.58N/A
20242024-12-31USD -0.02-96.2%
20252025-12-31USD -0.12471.6%
Yd Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-1080.0%
Q22025-06-3033.7%
Q42025-12-31N/A
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$408.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$29.20M

N/A

Employees

14

N/A

Net Income

-$2.21M

-112.9%

EBITDA

-$2.22M

-113.0%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$2.66M

-15.0%

Total Debt

$5.00K

-77.8%

Accounts Receivable

$558.86K

+112.7%

Inventory

$1.89M

+4968.6%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$5.00K

-70.4%

Return on Assets

-60.32%

N/A

Return on Invested Capital

-43.44%

N/A

Free Cash Flow

-$298.19K

+49.7%

Operating Cash Flow

-$298.19K

+49.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ASMBAssembly Biosciences, Inc.
$20.28-0.88%
OBIOOrchestra BioMed Holdings, Inc.
$5.47-5.77%
ARCTArcturus Therapeutics Holdings Inc.
$10.73-3.07%
FULCFulcrum Therapeutics, Inc.
$3.68-0.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$7.88-14.81%
SPCXSpace Exploration Technologies
$144.75-9.14%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$82.11-20.47%
INTCIntel
$85.49-8.04%

Questions About YDES

What is the current price of Yd Bio?

Yd Bio is trading at $4.24 per share.

What is the 52-week range for Yd Bio?

Over the past 52 weeks, Yd Bio has traded between $1.70 and $18.57.

How much debt does Yd Bio have?

As of the most recent reporting period, Yd Bio reported total debt of $0.00.

How much cash does Yd Bio have on hand?

Yd Bio reported $6.31K in cash and cash equivalents in its most recent financial results.

What is Yd Bio’s dividend yield?

Yd Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services